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Abstract
Purpose Perivascular adipose tissue (PVAT) exerts an anti-contractile effect which is vital in regulating vascular tone. This effect
is mediated via sympathetic nervous stimulation of PVAT by a mechanism which involves noradrenaline uptake through organic
cation transporter 3 (OCT3) andβ3-adrenoceptor-mediated adiponectin release. In obesity, autonomic dysfunction occurs, which
may result in a loss of PVAT function and subsequent vascular disease. Accordingly, we have investigated abnormalities in obese
PVAT, and the potential for exercise in restoring function.
Methods Vascular contractility to electrical field stimulation (EFS) was assessed ex vivo in the presence of pharmacological
tools in ±PVAT vessels from obese and exercised obese mice. Immunohistochemistry was used to detect changes in expression
of β3-adrenoceptors, OCT3 and tumour necrosis factor-α (TNFα) in PVAT.
Results High fat feeding induced hypertension, hyperglycaemia, and hyperinsulinaemia, which was reversed using exercise,
independent of weight loss. Obesity induced a loss of the PVAT anti-contractile effect, which could not be restored via β3-
adrenoceptor activation.Moreover, adiponectin no longer exerts vasodilation. Additionally, exercise reversed PVAT dysfunction
in obesity by reducing inflammation of PVAT and increasingβ3-adrenoceptor and OCT3 expression, which were downregulated
in obesity. Furthermore, the vasodilator effects of adiponectin were restored.
Conclusion Loss of neutrally mediated PVAT anti-contractile function in obesity will contribute to the development of hyper-
tension and type II diabetes. Exercise training will restore function and treat the vascular complications of obesity.
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Abbreviations
EFS Electrical field stimulation
KPSS High potassium physiological salt solution
L-NMMA L-NG-monomethyl arginine citrate
NA Noradrenaline
NOS Nitric oxide synthase
OCT Organic cation transporter
PSS Physiological salt solution
PVAT Perivascular adipose tissue
TNFα Tumour necrosis factor alpha
Introduction
Perivascular adipose tissue (PVAT) is a highly metabolically
active tissue which surrounds the majority of blood vessels
and contributes to the modulation of vascular tone [1–3].
Previously, we have presented evidence that the mechanisms
of this effect are mediated via the sympathetic nervous system
and are two-fold [4]; first, sympathetic nerve-derived nor-
adrenaline (NA) activates adipocyte β3-adrenoceptors, which
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triggers the release of the vasodilator adiponectin. Second,
excess NA is sequestered by adipocytes via organic cation
transporter 3 (OCT3). In obesity, PVAT function is lost,
which may contribute to development of metabolic syndrome
[5–7]. However, the mechanisms behind this loss of function
are unclear.
It is well known that in obesity, pathological over-activity
of the sympathetic nervous system occurs [8, 9]. Cardiac β-
adrenoceptors become desensitised in heart failure, as a result
of sympathetic nerve over-activity [10]. It is possible that in
PVAT, increased sympathetic activity could result in a
desensitisation of β3-adrenoceptors, leading to reduced
adiponectin release. Bioavailability of adiponectin has already
been demonstrated to be reduced in human obesity [11], hy-
pertension [12], and type II diabetes [13].
In obesity, PVAT morphology changes, and adipocyte size
and number increase. However, there is no increase in blood
supply, leading to hypoxia and chronic inflammation [14, 15].
By subjecting human and mouse mesenteric arteries to hyp-
oxia, the loss of the PVAT anti-contractile effect can be rep-
licated [6, 16]. There is substantial evidence for the role of
inflammation in the loss of PVAT function [17]. Hypoxia-
induced loss of anti-contractile function is prevented in the
absence of macrophages from the PVAT [16]. Moreover, cy-
tokine antagonists can be used to rescue hypoxia-induced
damage to PVAT function [6]. This suggests that hypoxia
induces an inflammatory response involving classical macro-
phage activation, leading to the release of cytokines into the
local environment, which damages the adipocytes.
Furthermore, hypoxia-induced damage can also be rescued
using free radical scavengers [6, 16, 18], illustrating that hyp-
oxia causes oxidative stress, which can ultimately cause dam-
age to the surrounding environment.
The role of adiponectin in the inflammatory response may
contribute to insulin insensitivity. Adiponectin is an inhibitor
of the cytokine tumour necrosis factor-α TNFα), which in-
hibits insulin signalling [19–22]. Therefore, reduced levels of
adiponectin will increase TNFα-mediated inhibition of insulin
signalling. Furthermore, TNFα expression is increased in obe-
sity [22], further inhibiting the vasodilator effects of insulin in
skeletal muscle, reducing blood flow and glucose uptake, and
leading to type-II diabetes.
Sympathetic nerves play a role in recruiting inflammatory
mediators, and a number of studies have demonstrated that
exercise, which is considered to be healthy sympathetic stim-
ulation, can reduce inflammation in obesity [23–26]. In a
study of inflammation in skeletal muscle, forced interval train-
ing in high fat-fed mice significantly reduced macrophage
infiltration [23]. Interestingly, these effects were independent
of weight loss. In a similar study using forced exercise, mac-
rophage infiltration and inflammatory cytokine expression
were reduced in the adipocytes of epididymal fat pads of
obese exercised trained mice, again independent of weight
loss [25]. Another study using obese mice provided with a
wheel for voluntary exercise [24] demonstrated significant
improvements in insulin-sensitivity, glucose tolerance, and
reduced total body fat mass and exhibited a significant reduc-
tion in inflammatory cytokine expression including TNFα. In
diabetic obese human patients, exercise has been shown to
reduce TNFα and interleukin-6 expression in subcutaneous
adipose [27]. The results of these studies could be applied to
reduce macrophage infiltration and inflammatory cytokine ex-
pression in PVAT surrounding resistance arteries, reversing
obesity-induced damage to PVAT, and alleviating the vascu-
lar complications of obesity, i.e., hypertension and diabetes.
The beneficial effects of exercise on brown adipose
tissue function surrounding the aorta has been well docu-
mented [28–31]; however, the effects of exercise on white
mesenteric PVAT function and small resistance arteries
have not yet been characterised. Previous weight loss
studies such as bariatric surgery [32], and caloric restric-
tion [33] have shown success in restoring PVAT function
in obesity. In addition, pharmacological intervention to
increase endothelial nitric oxide synthase (NOS) phos-
phorylation in obesity successfully restored function of
aortic PVAT [34]. Alongside improvements in PVAT
function, these studies also demonstrated improvements
in insulin sensitivity and blood pressure, highlighting the
importance of restoring PVAT function to treat the vas-
cular complications of obesity.
The present study was designed to examine the mecha-
nisms of PVAT dysfunction in obesity and the potential for
a significant lifestyle intervention in restoring function. We
tested the hypothesis that a loss of PVAT function in obesity
can be reversed via exercise. We anticipate that in obesity,
PVAT becomes inflamed, and expression of β3-
adrenoceptors and OCT3 are reduced. These changes in the
PVAT environment will be reversed by exercise. In addition,
we hypothesise that the resultant symptoms of metabolic syn-
drome in obesity will be alleviated by exercise.
Materials and Methods
Animal Care and Ex Vivo Measurements
All experiments were performed in accordance with the ap-
propriate Home Office project licence and complied with the
UKAnimal (Scientific Procedures) Act 1986. Male C57BL/6j
mice were randomly assigned to three groups; control, obese,
and exercised obese (see below) and aged until 18–20 weeks.
Animals were housed under a 12-h light/12-h dark cycle and
provided with food and water ad libitum. The body weights of
all groups were recorded every 2 weeks from 8 weeks of age.
Mice were fasted overnight and sacrificed using CO2 asphyx-
iation. Prior to sacrifice, blood pressure was recorded in
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conscious, restrained animals using the CODA tail cuff blood
pressure monitoring system (Kent Scientific, USA).
Immediately after sacrifice mixed blood samples were collect-
ed by severing the thoracic aorta. Blood glucose concentration
was measured immediately using an automatic blood glucose
system (Contour, Bayer Consumer Care AG, Basel,
Switzerland). Following euthanisation, the mesentery was ex-
posed and removed. Epididymal fat pads, hearts, and kidneys
were collected and weighed.
Control Mice
Control mice were fed a standard chow diet ad libitum (7.42%
fat, cat no. BK001, SDSDiets, UK) until they were euthanised
at 18–20 weeks old (n = 20).
Obese Mice: Diet-Induced Obesity
Male C57BL/6j mice (Harlan Laboratories, UK) were pur-
chased at 6 weeks old and allowed a 2-week acclimatisation
period before being placed on a 60% kcal from fat diet (cat no.
824054, SDS Diets, UK) ad libitum for 10–12 weeks and
euthanised at 18–20 weeks (n = 44). A 10–25% increase in
body weight as compared with age-matched controls is con-
sidered as moderate obesity in rodents [35]; therefore, to elim-
inate mice which may be resistant to obesity, mice with less
than a 10% increase in body weight as compared with healthy
controls were excluded from this study.
Exercised Obese Mice
For exercised obese mice, male C57BL/6j mice followed the
diet-induced obesity protocol as described above. At week
five, forced swim training commenced. Mice were initially
exercised for 15 min once a day, and the duration of exercise
increased in daily increments of 15 min until reaching a final
duration of 60 min. From week six, mice were exercised five
times per week. Mice were swum in tanks with a surface area
of 2,500 cm2 and a depth of 35 cm. Water temperature was
maintained at 32–35 °C. At the end of the exercise, mice were
carefully towel dried and kept in a drying enclosure at 30 °C
for 1 hour. All mice were able to complete this training. This
exercise regime was continued until mice were aged 18–
20 weeks before euthanising [36] (n = 20).
For the exercised obese model, there were two additional
control groups. The first group was a diet-induced obesity
group, which were high fat fed as described above, and were
euthanised after 5 weeks (the time point at which exercised
groups commenced training) to examine mouse phenotype
and PVAT func t ion a t th i s t ime poin t (n = 10;
Supplementary Figure 1). This control was used to determine
that PVAT function is already lost by this time point, resulting
in hypertension and hyperglycaemia, confirming that exercise
reverses dysfunction as opposed to preventing dysfunction.
Another control group of mice were maintained on a standard
chow diet and exercised along the same time line as the obese
exercised group; five times per week for 60 min (n = 8;
Supplementary Figure 2). There were no changes in PVAT
function or the phenotype of these mice, eliminating the pos-
sibility that the stress of water exposure and/or exercise is the
cause for any changes in exercised obese mice. For all animal
model timelines, see Supplementary Figure 3.
Blood Plasma Studies
Collected blood samples were centrifuged at 3000×g for
10 min at 4 °C to separate plasma. Plasma samples were then
stored at − 80 °C until required. Concentration of plasma NA,
adiponectin, and insulin was measured using commercially
available ELISA kits according to manufacturer’s instructions
(Table 1). All samples and standards were measured in dupli-
cate, and the optical density of the zero standard was
subtracted from each value. Standard curves were fitted using
non-linear regression analysis with a sigmoidal four parameter
logistic curve to interpolate values.
Wire Myography
Second-order mesenteric arteries were prepared as previously
described [37]. Arterial segments (< 250 μm) with PVAT re-
moved or left intact were dissected in ice cold physiological
salt solution (PSS, in mmol L−1; NaCl, 119; KCl, 4.7;MgSO4,
1.17; NaHCO3, 25; KH2PO4, 1.17; EDTA, 0.03; glucose, 5.5;
and CaCl2, 1.6) and were mounted on 40-μm diameter wires
in a wire myograph (Danish MyoTech, Denmark). Arteries
were allowed to equilibrate for 30 min at 37 °C in PSS bub-
bled with 95% air/5% CO2 to maintain a pH of 7.4. Following
equilibration, vessel starting tension was standardised using a
standard normalisation procedure [38]. Vessels were left for a
further 30-min equilibration period. To test vessel viability,
vessels were challenged with high K+ PSS (KPSS, in mmol
L−1; NaCl, 63.7; KCl, 60; MgSO4, 1.17; NaHCO3, 25;
KH2PO4, 1.17; K2 EDTA, 0.03; glucose, 5.5; and CaCl2,
1.6). Vessels were stimulated using an electrical field stimu-
lation protocol over a frequency range of 0.1–30 Hz (20 V, 4 s
stimulus duration, 0.2 ms pulse duration) [37]. Stimulation
was conducted using a Danish MyoTech CS4 stimulator.
LabChart 7 acquisition software (RRID:SCR_001620, AD
Instruments, UK) was used to continuously record responses.
Pharmacological Assessment
Previously published pharmacological assessment which
has been conducted in control vessels were repeated in
obese and exercised obese vessels in this study [37]. β3-
adrenoceptor agonists and antagonists were used to
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delineate their role in mediating the vascular response to
EFS in the presence or absence of PVAT; following the
first EFS stimulation, β3-adrenoceptor agonist CL-
316,243 (10 μM) or β3-adrenoceptor antagonist
SR59230A (1 μM) was added to ±PVAT vessels and
incubated for 30 min, before re-stimulating the vessels.
The effects of globular adiponectin (5 μg/ml) were tested
on only −PVAT vessels. Vessels were stimulated once
and allowed to recover for 15 min before adding
adiponectin. The adiponectin was incubated for 5 min be-
fore repeating the EFS protocol.
To examine the role of nitric oxide and NA transport, a
third arterial preparation was used whereby a section of exog-
enous PVAT was suspended above a clean artery (Ref no.
[37] for illustration of all arterial preparations). This allowed
the removal of PVAT for incubation with OCT3 inhibitor
corticosterone (100 μM), and eliminated interference with
NA uptake within the artery.
Time controls were conducted alongside all experiments to
ensure that any change in vascular responsiveness was not a
time effect (data not shown).
Adiponectin Assay
To quantify adiponectin secretion from obese PVAT com-
pared with healthy controls, PVAT was collected from the
mesenteric bed of control and obese mice and weighed. As
previously described [4], harvested PVAT was incubated in
PSS for 30 min bubbled with 95% air/5% CO2 before stim-
ulating using EFS at 10 Hz for 4 s (20 V, pulse duration
0.2 ms). The supernatant was collected and stored at −
80 °C. An adiponectin ELISA kit (Table 1) was used to
quantify adiponectin secretion according to manufacturer
instructions. Concentration was determined through mea-
surement of absorbance using a plate reader (BioTek,
Northstar Scientific, UK) at 450 nm and was calculated
per 100 mg of PVAT to account for variation in the amount
of PVAT collected from each mesenteric bed.
Drug Preparations
CL-316,243, and SR59230A were obtained from Tocris bio-
sciences (R&D systems, UK) and dissolved in PSS.
Recombinant mouse globular adiponectin was obtained from
Generon (UK, cat no. cyt-432-50μg). Corticosterone (Sigma
Aldrich, UK) was dissolved in 100% ethanol. Vehicle controls
confirm no effect of 100% ethanol (data not shown).
Immunohistochemistry
β3-adrenoceptor, OCT3, and tumour necrosis factor alpha
(TNFα) expression was assessed in control, obese, and
exercised obese PVAT by immunohistochemistry [37].
In brief, sections of PVAT from control, obese, and
exercised obese mice embedded in KP-CryoCompound
(Klinipath BV, The Netherlands) and 12-μm sections
were made using a cryostat. Heat-induced antigen retriev-
al followed by blocking of exogenous peroxide activity
was performed. Sections were blocked with goat serum
before incubation with primary antibodies for β3-
adrenoceptors (10 μg/ml, Abcam, Cambridge, UK, cat
no. ab59685, RRID:AB_2225531), OCT3 (10 μg/ml,
S i g m a A l d r i c h , U K , c a t n o . A V 4 4 0 2 6 ,
RRID:AB_1854770), or TNFα (10 μg/ml, Abcam,
Cambridge, UK, cat no. ab6671, RRID:AB_305641)
overnight at 4 °C. Slides were then incubated with a bio-
tinylated goat anti-rabbit secondary antibody (2 μg/ml,
Abcam, UK, cat no. ab6720, RRID:AB_954902) for
1 hour at room temperature before addition of vectastain
avidin-biotin complex (Vector Laboratories, UK) and
3,3′-diaminobenzidine solution (Vector Laboratories,
UK) for detection of antibody binding. Images were cap-
tured using a colour camera (Leica DFC450, Leica
Microsystems, Germany) mounted on a microscope
(Leica DM5000, Leica Microsystems, Germany).
Mouse kidney was used as a positive control, and negative
controls were conducted using samples incubated with phos-
phate buffered saline in place of the primary antibody.
Controls are provided in Supplementary Figure 4.
Statistical Analysis
Data are expressed as the mean ± SEM. All statistical
analysis was performed using GraphPad Prism v7
(RRID:SCR_002798, GraphPad Software USA). P values
< 0.05 were considered statistically significant. Normal
Table 1 Commercially available ELISA kits used to measure plasma NA, adiponectin, and insulin
Antigen Name of kit Supplier Catalogue no. Sample dilution
Adiponectin Adiponectin mouse ELISA kit Life Technologies Ltd KMP0041 Plasma—1 in 20,000
PVAT supernatant—1 in 100
Insulin Insulin mouse ELISA kit Invitrogen EMINS 1 in 2
Noradrenaline NA/NE ELISA kit Elabscience E-EL-0047 None
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distribution was confirmed using the Shapiro-Wilk nor-
mality test, supported by Skewness and Kurtosis coeffi-
cients (using an acceptable range of ± 2).
Phenotype Data
Differences in mouse phenotype measures including
blood pressure, blood glucose, organ weights, and plasma
ELISA data were analysed using a one-way analysis of
variance (ANOVA) followed by a Tukey post hoc test to
compare individual groups. For body weight progression,
differences were tested using a two-way ANOVA. A min-
imum sample size of 20 was used for each group. For
blood pressure, the average of the 10 measurement cycles
was used from each mouse [39].
Wire Myography
Contractile responses were normalised to the maximum
contraction elicited with KPSS, as consistent with other
studies [6, 16, 37, 40] and are expressed as a percentage.
Differences between the frequency-response curves of
±PVAT vessels were tested using a two-way ANOVA,
with a Bonferroni post-hoc test. Before and after treat-
ments within the same vessel types were compared using
a repeated-measures ANOVA, again followed by a
Bonferroni post-hoc test. Due to expense, an n of 4 was
used for exogenous adiponectin experiments. For all other
experiments an n of 8 was used.
Immunohistochemistry
Quantitative analysis of immunostaining was performed
using ImageJ (RRID:SCR_003070, v1.47, NIH, USA).
Images were taken from five fields of view per mouse.
The intensities of staining for β3-adrenoceptors and
OCT3, which were localised to adipocyte membranes,
were quantified within/around five arbitrarily selected ad-
ipocytes, i.e., staining intensity per adipocyte, as opposed
to using a set sized area for staining. This was to account
for changes in adipocyte size. TNFα staining was quanti-
fied within the whole field of view. Correlation of adipo-
cyte area and intensity of adipocyte membrane staining
were assessed to confirm that changes in intensity were
not due to changes in adipocyte size (See Supplementary
data 5). Statistical differences were analysed using a one-
way ANOVA followed by a post hoc Tukey’s test to
compare individual groups. Sample sizes of five were
used for each group.
Results
High Fat Feeding Resulted in Metabolic Syndrome
and Autonomic Dysfunction, which Is Reversed Using
Exercise
Obesity was established in C57BL/6j mice by high fat feeding
for 10–12 weeks. High fat feeding resulted in a significant
increase in body weight in both obese and exercised obese
mouse groups (Fig. 1a, control n = 20, obese n = 44,
exercised n = 20. Control vs obese P < 0.0001, control vs
exercised obese P < 0.0001). The difference in body weight
became significant after 4 weeks of high fat feeding
(P < 0.01). At week 6, the exercised obese group commenced
swimming. This group exhibited no further significant in-
creases in weight gain; however, these mice did not lose any
weight. To confirm that changes in weight were due to in-
creases in fat depots and not muscle mass, epididymal fat pads
were removed and weighed (Fig. 1b, control n = 20, obese n =
44, exercised obese n = 20). High fat feeding resulted in a
significant increase in fat depots in both obese and exercised
obese groups (control vs obese P < 0.0001, obese vs exercised
obese P < 0.01, control vs exercised obese P < 0.0001).
High fat feeding resulted in significant elevations in both sys-
tolic and diastolic blood pressures in the obese group; however,
in the exercised obese group, blood pressure was comparable
with healthy control mice (Fig. 1c, n = 20 all groups. Both sys-
tolic and diastolic: control vs obese P < 0.01, obese vs exercised
obese P < 0.01, control vs exercised obese P > 0.05). There were
no changes in heart or kidneys weights (Supplementary Figure 6)
indicating that hypertension cannot be attributed to cardiac hy-
pertrophy or kidney dysfunction. In a similar fashion to blood
pressure, high fat feeding resulted in hyperglycaemia in the obese
group; however, following exercise, blood glucose concentration
normalised (Fig. 1c, control n = 20, obese n = 44, exercised
obese n = 20. Control vs obese P < 0.01, obese vs exercised
obese P < 0.01, control vs exercised obese P > 0.05).
ELISA kits were used to measure plasma insulin (Fig. 1e)
and NA (Fig. 1f) (control and obese groups n = 22, exercised
obese n = 20). Plasma insulin was significantly increased in
obesity, which combinedwith hyperglycaemia indicating pos-
sible type II diabetes. Insulin was reduced in the exercised
obese group (control vs obese P < 0.0001, obese vs exercised
obese P < 0.0001, control vs exercised obese P > 0.05), and
plasma NA was significantly reduced in obesity, indicating
autonomic dysfunction. In exercise, NA was restored to con-
trol levels (control vs obese P < 0.0001, obese vs exercised
obese P < 0.0001, control vs exercised obese P > 0.05).
Expression of the inflammatory cytokine TNFαwas exam-
ined using immunohistochemistry in sections of mesenteric
PVAT from control, obese, and exercised obese mice (Fig.
2; n = 5 all groups). In obese mice, staining intensity of
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TNFα in PVAT was significantly increased compared with
controls (P < 0.001). In obese exercised mice, expression of
TNFαwas significantly reduced as compared with both obese
(P < 0.0001) and control mice (P < 0.05) (for positive and
negative controls, see Supplementary Figure 4), suggesting
that exercise has substantial beneficial effects alleviating in-
flammation in obesity.
Exercise Successfully Restored PVAT Function in
Obesity
To examine the effects of obesity on sympathetic nerve func-
tion in PVAT, EFS profiles were generated in mesenteric re-
sistance arteries from obese mice (0.1–30 Hz, 20 V, 0.2 ms
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Fig. 1 High fat feeding results in obesity and metabolic syndrome which
is reversed by exercise. a Body weights of control, obese, and exercised
obese mice were recorded every 2 weeks (control n = 20, obese n = 44,
exercised n = 20). b Following sacrifice, epididymal fat pads were
removed and weighed (control n = 20, obese n = 44, exercised n = 20). c
Prior to sacrifice, blood pressure was recorded using a CODA tail cuff
system (n = 20 all groups). d Following sacrifice, blood was collected and
glucose concentration was measured using an automatic monitor (control
n = 20, obese n = 44, exercised n = 20). Blood was collected and
centrifuged to separate plasma. Plasma concentrations of insulin (e) and
NA (f) were measured using ELISA kits (control n = 22, obese n = 22,
exercised n = 20). Data shown are mean ± SEM (**P < 0.01,
****P < 0.0001) (NA: noradrenaline)
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significant difference between −PVAT and +PVAT vessels
(Fig. 3a; P > 0.05, n = 8). Therefore, electrical activation of
sympathetic nerves in obese PVAT no longer elicits an anti-
contractile effect. However, electrical activation of sympathet-
ic nerves in exercised obese PVAT elicited a significant anti-
contractile effect (Fig. 3b; P < 0.0001, n = 8), indicating that
exercise has restored PVAT function.
β3-Adrenoceptor Expression Is Downregulated in
Obesity but Improved with Exercised
In a previous study, we have indicated that PVAT function is
mediated in part by β3-adrenoceptors [37]; therefore, in an
attempt to rescue PVAT dysfunction in obesity, the effects
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Fig. 2 Exercise reduced inflammation in obesity. Sections of mouse
mesenteric PVAT from control mice (a), obese (b), and exercised obese
mice (c) were stained for TNFα. Scale bar represents 50 μm. Staining
intensity in the whole field of view was quantified (d). Data shown are
mean ± SEM. Differences were tested using a one-way ANOVA (n = 5
both groups, *P < 0.05, **P < 0.01, ****P < 0.0001) (TNFα: tumour
necrosis factor-α)
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Fig. 3 PVAT anti-contractile dysfunction in obesity is recused with ex-
ercise. Vessels with and without PVAT from obese (a) and exercised
obese (b) mice were subjected to EFS. Data shown are mean ± SEM
(n = 8 for both, ****P < 0.0001) (EFS: electrical field stimulation;
PVAT: perivascular adipose tissue)
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stimulations with EFS, ±PVAT vessels from obese mice were
incubated for 30 min with CL-316,243, before repeating the
stimulus (Fig. 4e). CL-316,243 had no effect on either
−PVAT or +PVAT vessels (P > 0.05, n = 8), indicating that
these receptors may be downregulated in obesity.
The expression of β3-adrenoceptors was examined
using immunohistochemistry in sections of mesenteric
PVAT from control, obese, and exercised obese mice
(Fig. 4a–d; n = 5 all groups). The intensity of staining in
the adipocyte membrane was quantified, and in obese
mice, expression of the adrenoceptor was significantly
reduced as compared wi th tha t in obese mice
(P < 0.0001). In exercised obese mice, expression of β3-
adrenoceptors is significantly increased compared with
obese mice (P < 0.01); however, expression is still signif-
icantly lower in exercised obese mice than in control mice
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Fig. 4 Exercise in obesity upregulates β3-adrenoceptor expression to
restore anti-contractile function. Sections of mouse mesenteric PVAT
from control mice (a), obese mice (b), and exercised obese mice (c) were
stained for β3-adrenoceptors. Scale bar represents 50 μm. Staining inten-
sity of adipocyte membranes was quantified (d, n = 5 all groups,
*P < 0.05, **P < 0.01, ****P < 0.0001). Following control responses to
EFS ±PVAT vessels, obese vessels were incubated for 30 min with CL-
316,243 (e, n = 8, P > 0.05), and exercised obese vessels were incubated
with SR59230A (d, n = 8, −PVAT vs +PVAT P < 0.0001****, +PVAT
vs +PVAT and SR59230A P < 0.0001****, −PVAT vs −PVAT and
SR59230A P > 0.05 , −PVAT vs +PVAT and SR59230A
P < 0.0001****). Data shown are mean ± SEM (PVAT: perivascular
adipose tissue)
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To determine if the increase in expression of β3-
adrenoceptors in exercise is sufficient to restore function, fol-
lowing the first EFS stimulation, ±PVAT vessels from
exercised obese mice were incubated with β3-adrenoceptor an-
tagonist SR59230A (Fig. 4f; n = 8). Similar to previously re-
ported data in control mice [37], SR59230A resulted in a sig-
nificant reduction in the PVAT anti-contractile effect (−PVAT
vs +PVAT P < 0.0001, −PVAT vs −PVAT and SR59230A
P > 0.05, +PVAT vs +PVAT and SR59230A P < 0.0001,
−PVAT vs +PVAT and SR59230A P < 0.0001). These results
indicate that exercise restored β3-adrenoceptor-mediated
PVAT function in obesity.
OCT3 Expression Is Downregulated in Obesity and Is
Reversed with Exercise
Wehave previously demonstrated that the PVAT anti-contractile
effect in health ismediated by a combination ofβ3-adrenoceptor-
mediated anti-contractile factor release, and NA uptake into ad-
ipocytes by OCT3 [37]. Therefore, using immunohistochemis-
try, we examined the expression of OCT3 in control, obese, and
exercised obese PVAT (n = 5 all groups; Fig. 5a–d). The
intensity of staining in the adipocyte membrane was quantified,
and in obese mice, expression of OCT3 was significantly de-
creased compared with control mice (P < 0.05) and control mice
(P < 0.0001, n = 5 for all groups). However, in the exercised
obese PVAT,OCT3 expressionwas significantly increased com-
pared with both control and obese groups (control vs exercised
obese P < 0.0001, obese vs exercised obese P < 0.0001) (for
positive and negative controls, see Supplementary Figure 4).
PVAT denuded vessels with sections of exogenous PVAT
suspended above were subjected to control EFS stimulations,
before removing the exogenous PVAT and incubating with
the OCT3 inhibitor corticosterone (Fig. 5e). Following 30-min
incubation, the exogenous PVATwas re-suspended above the
vessel, and the EFS protocol was repeated. Similar to previ-
ously published data in control mice [37], corticosterone in-
duced a partial inhibition of the anti-contractile effect
(P < 0.0001, n = 8). Next, the exogenous PVAT was removed
again and incubated with both corticosterone and SR59230A,
and the restored anti-contractile effect in exercised obese mice
was completely abolished (P < 0.0001, n = 8), suggesting that
the normal functioning of both β3-adrenoceptors and OCT3
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Fig. 5 Exercise upregulates OCT3, restoring NA uptake into adipocytes.
Sections of mouse mesenteric PVAT from control mice (a), obese mice
(b), and exercised obese mice (c) were stained for OCT3. Scale bar
represents 50 μm. Staining intensity of adipocyte membranes was
quantified (d, n = 5 all groups, *P < 0.05, ****P < 0.0001). e
Following EFS, exercised obese vessels were incubated with
corticosterone alone for 30 min and subjected to a second EFS protocol.
Following this, vessels were incubated for a second time with
corticosterone plus SR59230A (SR) for 30 min, before being stimulated
with EFS for a final time (n = 8, −PVAT vs +exogenous PVAT P <
0.0001++++, +exogenous PVAT vs +exogenous PVAT and corticosterone
P < 0.0001****, −PVAT vs +exogenous PVAT and corticosterone P <
0.0001****, +exogenous PVAT vs +exogenous PVAT and corticoste-
rone + SR P < 0.0001****, −PVAT vs +exogenous PVAT and cortico-
sterone + SR P > 0.05). Data shown are mean ± SEM (EFS: electrical
field stimulation; NA: noradrenaline; OCT3: organic cation transporter 3)
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Adiponectin Is a Vasodilator in Exercised Obese
Arteries But Not in Obese Arteries
Previously, we have reported that adiponectin is the anti-
contractile factor released upon β3-adrenoceptor activation
[37]; therefore, we measured the secretion of adiponectin from
obese PVAT compared with secretion from healthy control
PVAT. PVATwas collected from the mesenteric beds of control
and obese mice and stimulated at 10 Hz for 4 s. The surrounding
supernatant was collected and adiponectin concentration was
quantified using an ELISA. The concentration of adiponectin
secreted from the obese PVAT was significantly reduced as
compared with the healthy control (Fig. 6a; n = 12 both
groups, P < 0.0001).
An ELISA kit was used to measure plasma adiponectin
(Fig. 6b) (control and obese groups n = 22, exercised obese
n = 20). Plasma adiponectin was significantly increased in
obesity and was reduced back to control levels with exercise
(control vs obese P < 0.01, obese vs exercised obese P < 0.01,
control vs exercised obese P > 0.05).
To determine if adiponectin presents a viable target for
treating the vascular complications of obesity, the effects of
globular adiponectin were tested in obese and exercised obese
mice. Following control stimulations with EFS, −PVAT vessels
were given 15min to recover before incubating with exogenous
adiponectin for a further 5 min. In obese vessels, exogenous
application of adiponectin no longer elicits a vasodilator effect
(Fig. 6c; P > 0.05, n = 4). However, in exercised obese mice,
adiponectin did cause a vasodilation (Fig. 6d; P < 0.0001, n =
4), indicating that the impaired vasodilator function of
adiponectin in obesity has been restored by exercise.
Discussion
This study has for the first time investigated the effects of
autonomic dysfunction on the PVAT effect in obesity and
the potential for exercise in restoring PVAT function in resis-
tance arteries. The main findings of this study were (1) in
obesity, PVAT becomes inflamed, and this inflammation is
reversed with exercise; (2) the sympathetic nerve-mediated
PVAT anti-contractile effect is lost in obesity, but can be
rescued using exercise; (3) reversal of PVAT dysfunction in
obesity using exercise is accompanied by normalised blood
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c d
Fig. 6 Adiponectin secretion in obesity is reduced and its vasodilator
function is lost. a Mesenteric PVAT from control and obese mice was
collected and adiponectin secretion per 100 mg was measured (n = 12
both groups, P < 0.0001****). Following sacrifice, blood was collected
and centrifuged to separate plasma. Plasma concentrations of adiponectin
(b) were measured using an ELISA kit (control n = 22, obese n = 22,
exercised n = 20, P < 0.01**). Following the control EFS protocol,
PVAT-denuded vessels from obese (c) and exercised obese (d) were
allowed 15 min to recover before incubating with recombinant globular
mouse adiponectin for 15 min and repeating the stimulus (n = 4 for both,
P < 0.0001****). Data shown are mean ± SEM (EFS: electrical field
stimulation; PVAT: perivascular adipose tissue)
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pressure, blood glucose, and plasma insulin, independent of
weight loss; (4) expression ofβ3-adrenoceptors and OCT3 are
downregulated in obesity, and activation of β3-adrenoceptors
cannot restore function; (5) adiponectin secretion from mes-
enteric PVAT is reduced in obesity; and (6) the vasodilator
function of adiponectin is lost in obesity but can be rescued
using exercise.
We found that 10–12 weeks of high fat feeding induced in-
creased adiposity, hypertension, and hyperglycaemia. Plasma in-
sulin was also increased threefold, which, in combination with
hyperglycaemia, would suggest that these mice may have type II
diabetes, although glucose tolerance testing is required to con-
firm. In humans, metabolic syndrome is defined by a combina-
tion of at least three out of five conditions: abdominal obesity,
hypertension, type-II diabetes, hypertriglyceridemia, and hyper-
cholesterolemia [41]. Therefore, these results are indicative of
metabolic syndrome. Consistent with other exercise studies, we
have demonstrated that exercise relieves the vascular and meta-
bolic complications of obesity, i.e., hypertension,
hyperglycaemia, and hyperinsulinemia [42–44]. These findings
were independent of weight loss, which fits with the “fat but fit”
hypothesis, proposing that cardiorespiratory fitness may be a
more important determinant of mortality than weight [45].
Hypertension and type II diabetes are major risk factors in
CVD and contribute to the short life expectancy of obese pa-
tients; therefore, treatment of these vascular diseases using this
exercise model may extend the life expectancy of obese patients.
We reported a reduced level of circulating NA in our obese
mouse model, and a similar reduction in plasma NA in obesity
has been reported in human patients [46]. However, measure-
ments of plasmaNA and urinarymetabolites are only indicative
of autonomic dysfunction and not nerve activity, as these mea-
surements do not take into account dysfunction that may be
occurring downstream, e.g., NA uptake into the periphery
[47]. Therefore, reduced circulating NA does not mean reduced
nerve activity and only confirms dysfunction [46]. In obesity, it
is widely accepted that sympathetic nerves become overactive
in both rodents and humans [8, 9, 48]. Indirect recordings such
as plasma NA or responses to autonomic blockade are often
used for a rough guide on changes in autonomic function; how-
ever, direct recordings of sympathetic nerve activity would pro-
vide amore accurate investigation of autonomic over-activity in
our model of obesity [49]. However, currently, there are no
commercially available telemeter devices to measure sympa-
thetic nerve activity in conscious mice. Direct recordings can
be taken in anaesthetised mice, but these preparations raise
concerns regarding the effects of anaesthetic on sympathetic
nerve activity and arterial blood pressure, which is intimately
linked to sympathetic nerve activity and is greatly reduced un-
der anaesthesia [50]. There has been some success by Hamza
and Hall [51] in developing an experimental method for direct
recordings of renal sympathetic nerve activity in conscious
mice; however, the viability of nerve recordings decreased
rapidly in the days following surgery, making this method un-
suitable in its current state for recording nerve activity before
and after high fat feeding.
Activation of β3-adrenoceptors using an agonist did not res-
cue loss of function, indicating either dysfunction or downreg-
ulation of the receptor. There are no agonists available for
OCT3; therefore, we were unable to determine if pharmacolog-
ical manipulation of this transporter could restore function. In
this study, we have indicated a downregulation of both β3-
adrenoceptors and OCT3 using immunohistochemistry, which
is not a quantitative measure and is therefore a limitation of this
study. In heart failure, over-activity of sympathetic nerves re-
sults in desensitisation and internalisation of β3-adrenoceptors
[10]. In future studies, we aim to demonstrate using western
blots and quantitative PCR that a similar process is occurring in
obese adipose tissue, resulting in a reduction in expression of
β3-adrenoceptors and OCT3. It has been suggested that β3-
adrenoceptors are a potential target for the treatment of hyper-
tension in obesity, as agonists have been shown to be hypoten-
sive in healthy canines and rodents [52, 53]; however, reduced
expressions of β3-adrenoceptors in obesity make the applica-
tion of an agonist redundant. Reduced expression of β3-
adrenoceptors in obesity has been shown in a number of obese
mouse models [54]; however, this is the first study to report a
change in expression of OCT3 in obesity.
The reduced expression of β3-adrenoceptors in obesity re-
sults in a reduction in adiponectin secretion as demonstrated in
this study using an ELISA. Reduced secretion of the vasodilator
adiponectin will contribute to increases in arterial tone and
blood pressure. Paradoxically, we found plasma adiponectin
levels to be elevated in our obese mice. Studies have shown
that adiponectin clearance in obesity is impaired [57]; therefore,
it is possible that this has resulted in an accumulation of
adiponectin in the plasma of our mice. Typically, plasma
adiponectin is accepted as reduced in obesity [11, 55, 56].
The obese model used here is a relatively acute model of obe-
sity. It is possible that this accumulation of adiponectin is an
early compensatory mechanism in obesity in response to re-
duced secretion, and levels will decline with chronic obesity.
Nonetheless, with exercise, plasma adiponectin levels were
returned to normal, indicating a restorative effect of exercise
on adiponectin secretion and clearance.
To determine if administration of adiponectin would be use-
ful in obesity, we applied exogenous adiponectin to obese ar-
teries. However, the vasodilator effects of adiponectin were
absent. This may suggest that increased plasma adiponectin
may have resulted in desensitisation of receptors. In addition,
adiponectin causes vasodilation via mechanisms dependent up-
on adenosine monophosphate-activated protein kinase
(AMPK) [58, 59]. In obesity, phosphorylation of AMPK is
reduced; supressing AMPK activity [60, 61]. It is possible that
the lack of adiponectin function in obesity may be due to chang-
es in AMPK activity in the vascular smooth muscle and
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endothelial cells. However, in this study, we were able to re-
store the vasodilator effects of adiponectin in obesity using
exercise.
This is the first study to demonstrate a restoration of the
PVAT anti-contractile effect in resistance arteries in obesity
using exercise. Moreover, these findings were independent of
weight loss. One of the beneficial effects in PVAT of exercise
is reduced inflammation. There is a clear reduction in the
expression of TNFα, an important inflammatory marker [22]
in exercised obese PVAT. This will therefore reduce the dam-
age caused to PVAT by inflammation. The results of the
TNFα expression studies are consistent with previous studies
in our laboratory, whereby bariatric surgery in obese patients
restored anti-contractile function in PVAT and reduced in-
flammation in PVAT, whilst patients were still in the
obese body mass index (BMI) range [32].
We are the first to demonstrate that expression of β3-
adrenoceptors and OCT3 are increased by exercise.
Expression levels of OCT3 have been returned to control levels,
whereas expression of β3-adrenoceptors is still below normal.
However, the efficacy of the β3-adrenoceptor antagonist in re-
ducing the anti-contractile effect alone, and abolishing the anti-
contractile effect in combination with the OCT3 inhibitor
would suggest that the expression of β3-adrenoceptors has in-
creased enough to restore the healthy PVAT anti-contractile
mechanism. Therefore, healthy sympathetic activity, i.e., exer-
cise, has restored PVAT’s ability to release an anti-contractile
factor upon β3-adrenoceptor activation, and the ability to trans-
port NA into adipocytes via OCT3, preventing the NA from
reaching the blood vessel and eliciting contraction.
Many studies have indicated that exercise can induce
“beiging” of white adipose tissue [62–65]. This process, by
which white adipocytes can be stimulated to differentiate into
an intermediate between white and brown adipocyte, results in
“beige” or “brite” adipocytes which can participate in thermo-
genesis, making it metabolically beneficial [63, 66]. The degree
of beiging is dependent on the duration and type of exercise [67,
68], and it is possible that this process has been induced in the
exercise model used here. Furthermore, both β3-adrenoceptors
[69–72] and OCT3 [73] have been indicated in beiging. In
future studies, we will aim to investigate the potential role of
beiging in the beneficial effects of our exercise model.
Dysfunction of the sympathetic nervous system in obese
PVAT results in a loss of the PVAT anti-contractile effect,
which may be contributing to the development of hyperten-
sion and type II diabetes. The over-activity of sympathetic
nerves in obesity causes downregulation of β3-adrenoceptors
and OCT3, resulting in a loss of PVAT function. Moreover,
obese arteries are no longer responsive to adiponectin.
Healthy sympathetic activity, i.e., exercise, restored the nor-
mal PVAT anti-contractile mechanism in obesity, indepen-
dent of weight loss. Exercise reduced inflammation of
PVAT and increased expression of β3-adrenoceptors and
OCT3 to restore function. Moreover, the vasodilator function
of adiponectin was restored. As a result of repaired PVAT
function, the vascular complications of obesity, hypertension,
and type II diabetes were reversed, indicating exercise as an
effective treatment for obesity-related illnesses, highlighting
the importance of exercise as a first line of treatment in the
vascular complications of obesity.
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